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Abstract: In a series of previous studies, we demonstrated that the photodynamic therapy (PDT),
as a widely used tool for treatment of glioblastoma multiforme (GBM), also site-specifically opens
the blood–brain barrier (BBB) in PDT-dose and age-related manner via reversible disorganization
of the tight junction machinery. To develop the effective protocol of PDT-opening of the BBB,
here we answer the question of what kind of photosensitizer (PS) is the most effective for the BBB
opening. We studied the PDT-opening of the BBB in healthy mice using commercial photosensitizers
(PSs) such as 5-aminolevulenic acid (5-ALA), aluminum phthalocyanine disulfonate (AlPcS), zinc
phthalocyanine (ZnPc) and new synthetized PSs such as galactose functionalized ZnPc (GalZnPc).
The spectrofluorimetric assay of Evans Blue albumin complex (EBAC) leakage and 3-D confocal
imaging of FITC-dextran 70 kDa (FITCD) extravasation clearly shows a revisable and dose depended
PDT-opening of the BBB to EBAC and FITCD associated with a decrease in presence of tight junction (TJ)
in the vascular endothelium. The PDT effects on the BBB permeability, TJ expression and the fluorescent
signal from the brain tissues are more pronounced in PDT-GalZnPc vs. PDT-5-ALA/AlPcS/ZnPc.
These pre-clinical data are the first important informative platform for an optimization of the PDT
protocol in the light of new knowledge about PDT-opening of the BBB for drug brain delivery and for
the therapy of brain diseases.
Keywords: blood–brain barrier; photodynamic effects; photosensitizers; drug brain delivery
1. Introduction
The blood–brain barrier (BBB) is a major hindrance for the effective delivery of therapeutic
compounds to the brain [1]. Various strategies to overcome the BBB have been investigated, including
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direct intranasal drug delivery [2], focused ultrasound [3], intra-arterial infusion of mannitol [4],
or direct intracranial infusion [5]. Nowadays the photodynamic effect on the BBB is actively discussed
as a new strategy for drug brain delivery, especially for post-surgery therapy of glioblastoma multiforme
(GBM) [6]. Photodynamic therapy (PDT) is a widely used tool for therapy of GBM [7,8]. The PDT is
based on a laser excitation of photosensitizers (porphyrins, chlorins, and many other photosensitive
dyes) that is accompanied by producing singlet oxygen (1O2) which oxidizes biomolecules causing
cancer cell apoptosis and/or necrosis through plasma and mitochondrial membrane rupture. Recently,
it has been revealed that PDT can also effectively and site-specifically open the BBB [9–14]. For the
first time a targeted disruption of the BBB following a 5-aminolevulenic acid (5-ALA) mediated PDT
via the opened skull was shown by Hirschberg et al. in 2008 [9]. Later Madsen et al. demonstrated
a non-invasive PDT-opening of the BBB for macrophages using a 670 nm laser and aluminum
phthalocyanine disulfonate (AlPcS) [10]. In a series of our experimental studies of PDT-5-ALA-opening
of the BBB we have analyzed the optimal dose of 635 nm irradiation and 5-ALA, the time window
for PDT-opening/closing of the BBB, mechanisms underlying this phenomenon and age differences
in PDT-related increase in the BBB permeability, which is consistent with other data [11–15]. In this
work we attempt to answer the question of what kind of photosensitizer might be most effective for
PDT-opening of the BBB. Therefore, we analyzed the BBB permeability to high molecular weight
molecules using two types of photosensitizers (PS) such as 5-ALA and phthalocyanines (PCs) since
their application for drug delivery systems has been shown in other studies [16,17].
Phthalocyanines (PCs) are synthetic dyes that were obtained and described already in 1907 by
Braun and Tcherniac [18]. PCs consist of four units of isoindoles bridged by nitrogen atoms and which
form one aromatic heterocyclic structure. Main photophysical characteristics of PCs are: absorption
spectrum with two important bands—the weak Soret-band located in the UV zone of the spectrum
with maximum at 350–360 nm and the Q-band in the red zone of the visible spectrum at around
670–680 nm. The high intensity of the latter band, due to values of the molar extinction coefficient
1 × 105 M−1 cm−1 (two orders of magnitude higher than that at most of porphyrins) is one of the main
characteristics of these dyes [19]. Photochemical properties of PCs are strongly influenced by the
nature of the coordinated central metal ion. Thus, the presence of diamagnetic elements in the central
cavity, such as zinc (II), aluminum (III), gallium (III) or silicon, gives them a high triplet quantum yield
(ΦT > 0.4) with long triplet lifetimes (τT > 100 µs). Triplet energy states with energy of about 1.2 eV,
make them efficient generators of singlet oxygen with values of singlet oxygen quantum yields (SOQY)
more than 0.4 [20,21].
We hypothesize that functionalization of PCs by galactose might be more effective for the
PDT-mediated BBB opening due to enhancing the trans-endothelial permeability by galactose via
activation of protein kinase C (PKC), a family of kinases vital to intracellular signaling that is a
common effect of monosaccharides on vascular endothelium [22,23]. Our previous results indicate
that functionalization of PCs by galactose is more favorable than zinc only due to their chemical
properties [24,25]. Based on these facts, here we study the BBB opening in healthy mice using the
PDT protocol with different PS, including commercial PS such as 5-ALA and AlPcS as well as new
synthesized PS such as zinc phthalocyanine (ZnPc) and functionalized by galactose ZnPc (GalZnPc).
2. Materials and Methods
2.1. Subject
Experiments were performed in mongrel male mice (25 g) in accordance with the Guide for the Care
and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH Publication No.
85-23, revised 1996), protocols were approved by the Institutional Review Board of the Saratov State
University (Protocol 7, 07.02.2017). The rats were housed at 25 ± 2 ◦C, 55% humidity, and 12 h:12 h
light—dark cycle. Food and water were given ad libitum.
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The experiments were performed in the following groups: (1) three control groups, including
mice without PDT (1a) the intact mice, (1b) no laser, (1c) no PS, injection of physiological saline (sham
group); (2) four PDT groups, including mice after PDT using different PSs (2a) 5-ALA; (2b) AlPcS; (2c)
ZnPc; (2d) GalZnPc; n = 10 in each group in all series of experiments.
2.2. Photodynamic Treatment Protocol
The mice were anaesthetized with ketamine (100 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.)., and
fixed in a stereotactic frame. The PDT was performed 30 min after intravenous injection of PS (5-ALA,
ALASENS, Niopik Inc., Moscow, Russian Federation, 20 mg/kg); AlPcS, ZnPc and the galactosilated
zinc phtalocianine (GalZnPc) were synthesized according to procedures described in our previous
papers [18,19,26,27] with modifications depending on coordinating metal. Photodynamic treatment
protocol is presented on Scheme 1.
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The heating of the brain tissue caused by exposure to light was monitored by using a thermocouple
data logger (Pico Technology, USB TC-08, Cambridgeshire, UK).
No significant temperature increase was observed during the light irradiation of the brain tissues.
The temperature rise did not exceed 2 ◦C above the mouse body level of 28 ◦C for the irradiation
doses chosen.
2.3. Spectrofluorometric Assay of Evans Blue Albumin Complex (EBAC) Extravasation
Three days before the experiments, the polyethylene catheter was implanted into the femoral
vein for intravenous injection of Evans blue dye in awake mice. The implantation of a catheter was
performed under anesthesia with ketamine (100 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). Before
PDT Evans blue dye was injected and circulated in the blood for 30 min in accordance with our
protocol [11,12]. At the end of the circulation time, mice were decapitated; their brains and blood were
quickly collected and placed on ice (no anti-coagulation was used during blood collection). Prior to
brain removal, the brain was perfused with saline to wash out the remaining dye in the cerebral vessels.
The detailed protocol of Evans blue albumin complex (EBAC) extraction and visualization was
published by Wang et al. [28]. Briefly, the isolated brains were cut into small pieces and incubated with
saline (1:3) for 60 min to enable the soluble substances to dissolve. Then the solutions were centrifuged
at 10,000× g for 10 min to sediment the non-dissolved parts. The supernatants that contained the brain
solutes were treated by 50% trichloroacetic acid—TCA (1:3), centrifuged again at 10,000× g for 20 min
to remove precipitated molecules. The final supernatants were incubated in 95% ethanol to increase
the optical signals for the spectrofluorometric assay (620 nm/680 nm, Agilent Cary Eclipse, Agilent,
USA). The standard calibration curve was created and used for calculation of the EBAC concentration
(µg per g of tissues).
Despite the fact that a quantitative analysis of EBAC is still the most commonly used marker
of the BBB integrity, there are some problems arising from its ex vivo and in vivo application: about
15% of Evans blue dye remains on the endothelium of cerebral vessels; Evans blue dye can be taken
by red blood cells and astrocytes [29]. Therefore, for qualitative and quantitative assessment of the
BBB integrity, we used additional methods for the analysis of the BBB permeability to low and high
molecular weight molecules.
2.4. Confocal Microscopy of FITC-dextran 70 kDa Extravasation
Fluorescein isothiocyanate (FITC)-dextran 70 kDa (FTICD) was used as an additional valuable
tool to characterize the BBB permeability to high molecular weight molecules. The protocol for FITCD
to assess the BBB disruption using confocal microscopy is described in detail in [30]. Briefly, before (in
the intact mice) or 1 h/4 h/24 h after PDT, FITCD 70 kDa (1 mg/25 g mouse, 0.5% solution in saline,
Sigma-Aldrich) was injected into the tail vein and allowed to circulate for 2 min. Afterward mice were
decapitated and the brains were quickly removed and fixed in 4% paraformaldehyde for 24 h, cut
into 50-µm thick slices on a vibratome (Leica VT 1000S Microsystem, Germany) and analyzed using
a confocal microscope (Olympus FV10i-W, Olympus, Japan). Approximately 8–12 slices per animal
from cortical and subcortical (excepting hypothalamus and choroid plexus where the BBB is leaky)
regions were imaged. The pericytes marker NG2 (1:500, ab 50009, Abcam, Cambridge, UK) was used
for labeling of the cerebral vessels using the protocol for immunolabelling assay.
2.5. Immunohistochemical Assay
Mice were euthanized with an intraperitoneal injection of a lethal dose of ketamine and xylazine
and intracardially perfused with 0.1 M of phosphate-buffered saline for 5 min. Afterward, the brains
were removed and fixed in 4% buffered paraformaldehyde for one day and in 20% sucrose for another
day. Fluorescence of antigens on free-floating sections was evaluated using the standard method of
simultaneously combined staining (Abcam Protocol). Brain slices (50 µm) were blocked in 150 µL 10%
bovine serum albumin/0.2% Triton X-100/PBS for 2 h, then incubated overnight at 4 ◦C and 2 h at room
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temperature with Clauding-5 (CLND-5, 1:500; Santa Cruz Biotechnology, sc-28670, Santa Cruz, USA);
Occludin (Occ, 1:500; Abcam, ab58803, Cambridge, USA); junctional adhesion molecule (JAM, 1:500,
Abcam, ab1316, Cambridge, USA). After several rinses in PBS, the slides were incubated for 3 h at
room temperature with fluorescent-labeled secondary antibodies on 1% BSA/0.2% Triton X-100/PBS
(1:500; Goat A/Rb, Alexa 555- Abcam, UK, ab150078). Confocal microscopy of the mice cerebral cortex
was performed using a fully automated confocal laser scanning microscope with water immersion
Olympus FV10i-W (Olympus, Japan). The ImageJ software was used for image data processing and
analysis. The areas of fluorescence from TJ were calculated using the plugin “Analyze Particles” in the
Analyze tab, which calculates the total area of antigen-fluorescence—the indicator “Total Area.” In all
cases, 10 regions of interest were analyzed.
2.6. Statistical Analysis
The results were reported as a mean value ± standard error of the mean (SEM). Differences from
the initial level in the same group were evaluated by the Wilcoxon test. Intergroup differences were
evaluated using the Mann–Whitney test and the ANOVA-2 (post hoc analysis with the Duncan’s rank
test). The significance levels were set at p < 0.05 for all analyses.
3. Results
3.1. Phthalocyanine Functionalization by Galactose
The synthetic procedure for the galactosilated phthalocyanine—galactopyranosyl Zn(II)Pc—is
according to the presented synthetic scheme (Scheme 2) and partly described in [31,32].
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In short, the synthesis procedure involves the following steps: 3-nitrophthalonitrile and
4-nitrophthalonitrile are suitable starting compounds for the synthesis of various non-peripheral and
peripherally substituted phthalocyanines. The synthesis of the starting phthalonitrile-substituted
galactopyranosyl groups (1) and (4)—precursors in the synthesis of phthalocyanines—proceeds via the
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mechanism of nucleophilic replacement of the NO2 group in DMF solution in the presence of a potassium
carbonate base. A further step of the synthesis procedure involves the preparation of tetra-substituted
conjugates of Zn(II) phthalocyanine with protected galactopyranose in a non-peripheral and a peripheral
position. The reaction is cyclotetramerization of the resulting substituted phthalonitriles, which is run
in a n-pentanol solution and in the presence of a catalyst: 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU)
under a nitrogen atmosphere.
The final step of the synthesis procedure consists in unblocking the protective isopropylidene
groups of the bound α-d-galactopyranose to ZnPc in a non-peripheral and a peripheral position
(respectively compounds 3 and 6). During the investigations, tetra-substituted Zn(II) phthalocyanine
conjugates with protected galactopyranose in a non-peripheral and a peripheral position were used
as final products: [n-GalZnPc, p-GalZnPc]. The compounds were chemically characterized and their
main absorption and fluorescence properties and the formation of singlet oxygen in their presence
were investigated.
3.2. Photodynamic Opening of the BBB Using Different PSs
In this session of experiments, we studied the PDT-opening of the BBB using different PSs,
including two commercial PSs such as 5-ALA and AlPcS as well as new synthetized ones, such as ZnPc
and its functionalized form GalZnPc.
Figure 1-I illustrates molecular formulas of photosensitizers used for PDT-opening of the BBB.
Figure 1-II,III demonstrate confocal imaging of the BBB permeability to FITCD before and after PDT.
In the control groups (no PDT, no laser or PSs), FITCD was observed only in the cerebral vessels
(Figure 1-I). PDT-5-ALA/AlPcS/ZnPc/GalZnPc induced strong FITCD extravasation from the cerebral
vessels into the brain tissues. The FITCD leakage was visualized by fluorescence outside the vessel
walls (Figure 1-II).
Spectrofluorimetric assay revealed laser dose-mediated increase in the BBB permeability to
EBAC 1 h after PDT-5-ALA/AlPcS/ZnPc/GalZnPc. Figure 1-IV illustrates more pronounced effects of
PDT-ZnPc-Gal on the EBAC leakage compared with other types of PSs (GalZnPc/AlPcS: 29.54 ± 0.02
vs. 18.64 ± 0.03, p < 0.001 for 2.5 J/cm2; 31.80 ± 0.03 vs. 20.37 ± 0.08, p < 0.001 for 5 J/cm2; 33.93 ± 0.05
vs. 23.18 ± 0.07, p < 0.001 for 10 J/cm2; GalZnPc/ZnPc: 29.54 ± 0.02 vs. 12.55 ± 0.05, p < 0.001 for
2.5 J/cm2; 31.80 ± 0.03 vs. 14.12 ± 0.01, p < 0.001 for 5 J/cm2; 33.93 ± 0.05 vs. 15.44 ± 0.05, p < 0.001 for
10 J/cm2; GalZnPc/5-ALA: 29.54 ± 0.02 vs. 1.18 ± 0.02, p < 0.001 for 2.5 J/cm2; 31.80 ± 0.03 vs. 1.09 ± 0.02,
p < 0.001 for 5 J/cm2; 33.93 ± 0.05 vs. 8.97 ± 0.05, p < 0.001 for 10 J/cm2). The level of EBAC in the brain
tissues after PDT-GalZnPc/AlPcS/ZnPc/5-ALA was 89-62-48-22-fold higher compared with the control
groups (average value for three control groups: the intact mice, no laser, no PSs), i.e., the effects of
PDT-GalZnPc on the BBB were 1.4-1.8-4.0 greater than PDT-AlPc1/ZnPc/5-ALA, respectively. Thus,
our results clearly demonstrate that all PSs are effective for PDT-mediated opening of the BBB. However,
functionalized GalZnPc gives even a stronger increase in the BBB permeability than 5-ALA, AlPcS,
and ZnPc, probably due to enhancing the transendothelial permeability by galactose [33,34].
No leakage of FITCD or EBAC was observed 4 h and 24 h after PDT, i.e., PDT-opening of the BBB
is associated with a rapid recovery of the BBB integrity.
The PDT-opening of the BBB independent of the type of PSs was accompanied by a similar
decrease in fluorescence of TJ proteins such as CLND, OCC, and JAM that can explain an increase
in the BBB permeability to EBAC and FITCD in mice 1 h after PDT. It is important to note that the
TJ fluorescence was over the normal value 4 h after PDT suggesting reversibility of PDT-mediated
changes in the BBB leakage.
The excitation and emission spectra of the investigated phthalocyanines are quite similar (see
Figure 2e–g), with the maxima of excitation and fluorescence respectively at 684 nm and 691 nm for
AlPcS, 675 nm and 680 nm for ZnPc, and 703 and 710 nm for GalZnPc in polar solution. In biological
tissues the maxima of emission are shifted by about 10–12 nm to a lower wavelength region due to the
influence of the microenvironment on the photosensitizer molecules.
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(I) The chemical formulas of the used PSs (A—GalZnPc; B—AlPcS; C—ZnPc; D—5-ALA) for the BBB
opening; (II) The confocal imaging of cerebral vessels (red color) filled by FITCD (green color) in the
normal state: A—the cerebral vessels are filled by FITCD (green color), B—the blood vessels marked by
NG2 (pericytes marker), C—merged A and B; (III) The confocal imaging of extravasation of FITCD
(green color, arrowed) from cerebral vessels (red color) into the brain tissues: A - the cerebral vessels are
filled by FITCD (green color), B—the blood vessels marked by NG2 (pericytes marker), C—merged A
and B, D and E—2-D and 3-D imaging of FITCD leakage; (IV) Spectrofluorimetric assay of EBAC level
in the brain tissues after PDT-opening of the BBB using different PSs (5-ALA/AlPcS/ZnPc/GalZnPc): *;
†; #—p < 0.001 vs. the control groups including the intact mice, mice after laser irradiation, mice treated
by PSs, respectively; n = 10 for each group and ◦—p < 0.001 between the experimental groups, at least
10 individual tissue sections taken for each animal for II and III; (V) The fluorescence of TJ proteins in
the control group (the intact mice), 1 h and 4 h after PDT-5-ALA/AlPcS/ZnPc/GalZnPc (n = 10 for each
group): **—p < 0.01, ***—p < 0.001 vs. the control group (the intact mice).
3.3. Fluorescence Spectra of Brain Tissues with Different PSs
In these studies, we evaluated the fluorescence signal from exogenous photosensitizers
accumulated in brain tissues after opening of BBB. The excitation was used on 400 nm for all
photosensitive drugs, using their Soret-band of absorption. The brain tissue fluorescence of a control
group of three mice without exposure to exogenous photosensitive drugs was compared to that of
photosensitized animals.
Initially, before red light irradiance of the brain, 5-ALA/PpIX fluorescence was pronounced in a
higher degree, in comparison with that of one of phthalocyanine compounds. Moreover 60 min after
irradiation with 635 nm due to opening of BBB barrier, an increase of this emission was observed in all
animals treated, see Figure 2a,b. Some increase of the photosensitizer concentration into brain tissues
was observed as well for different phthalocyanines used, namely AlPcS, ZnPc, and GalZnPc after
irradiation at 670 nm, but in general the fluorescent intensity observed in the case of phthalocyanine
accumulation in brain tissues is about 3 times lower than the emission observed from protoporphyrin
IX. The results, obtained with GalZnPc treated animals, are presented in Figure 2c,d.
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4. Discussion
In this pre-clinical work on healthy mice, we aimed to answer the question of what kind of
photosensitizer is more appropriate for PDT-opening of the BBB. To answer this question, we studied
PDT-opening of the BBB using commercial PS such as 5-ALA and AlPcS as well as new synthetized PS
such as ZnPc and functionalized its form GalZnPc. Our results reveal a dose-depended PDT opening
of the BBB using all types of PS. The PDT-opening of the BBB using 5-ALA and AlPcS also have
been shown by Hirschberg et al. [9], Madsen [10], and in our previous experiments [11–14]. Using
spectrofluorimetric assay for quantitative analysis of the BBB permeability to EBAC and confocal
imaging of FITCD extravasation, our results demonstrate that PCs induce stronger ECAB leakage
compared with 5-ALA. Among PCs, GalZnPc causes the more pronounced increase in the BBB
permeability to EBAC vs. AlPcS, ZnPc. Phthalocyanines generate singlet oxygen directly under light
irradiation [35], while 5-ALA does not produce single oxygen itself but only via metabolization in the
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cells to protoporphyrin IX [36]. These facts can explain the lesser PDT-5-ALA opening of the BBB to
EBAC compared with different forms of used phthalocyanines (AlPc\S, ZnPc, GalZnPc). The stronger
effect on the BBB permeability by GalZnPc can be due to enhancing the transendothelial permeability
by galactose via activation of protein kinase C (PKC), a family of kinases vital to intracellular signaling
that is a common effect of monosaccharides on vascular endothelium [22,23].
To better understand mechanisms responsible for PDT-induced opening of the BBB to high
molecular weight molecules (EBAC and FITCD), we explored PDT-related changes in the fluorescent
signal of TJ trans-membrane proteins such as CLND, OCC, and JAM. The fluorescence of these
molecular factors was analyzed before PDT (the control groups), 1 h after PDT (when BBB was opened),
and 4 h after PDT (when the BBB was closed and completely recovered). Our results uncovered
a decrease in the fluorescence of TJ proteins in the time of PDT-opening of the BBB with a rapid
normalization of the fluorescence of these proteins till the moment of BBB closing.
These findings are consistent with data of others showing that PDT has a direct effect on increasing
the gaps of the TJs between endothelial cells via changes of cytoskeleton and vascular tone loss due
to microtubule depolymerization [37–39]. One of the mechanisms by which PDT opens the BBB can
be an increase in the singlet oxygen/ROS production and development of oxidative stress that we
observed in our previous work using 5-ALA [14] and that was also described for phthalocyanines [35].
We assume that a PDT-induced increase in oxidative stress and associated with these changes in TJ
proteins might be one mechanism underlying PDT-related BBB opening.
5. Conclusions
Our pre-clinical results open a new application of PDT for drug brain delivery. The study of
reversible PDT-opening of the BBB using commercial PS such as 5-ALA and AlPcS as well as newly
synthesized ZnPc and GalZnPc reveal a stronger PDT-GalZnPc increase in the BBB permeability to
EBAC and FITCD vs. other tested PS. These data suggest that PDT-GalZnPc may prove to be a more
promising tool for the BBB opening and for drug brain delivery. The limitation of this work is the study
of PDT-opening of the BBB in healthy mice. We expect that PDT-opening of the BBB might be a useful
tool in the theranostics of gliomas that we will show in our further research. However, these findings
represent a first important informative platform that may help the development of novel strategies in
the therapy of brain diseases, via optimization of PDT protocol in the light of new insights of PDT
effects on the BBB permeability.
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